ABT
Abbott Laboratories Health Care Pharmaceutical Preparations S&P 500Russell 3000
$106.20Close
$212.1BMarket cap
$81.98 – $128.2152-week range
Mid-januaryNext report · estimated
Highlights
Strengths
- Tight base near its pivot pullbacks 14% → 9% → 8%; 0.1% below its $106.35 pivot
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Lagging the market RS 44 · weaker than 56% of stocks over 12 months
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
17%
1wk
up 2.4%
price change
1mo
up 8.1%
price change
12-month return
down 13%
market up 11% ·
its own down 24%
F-score
5 / 9
Mixed
Altman Z
5.43
Low risk
P/E
32.5×
price / earnings
PEG
—
P/E / EPS growth
P/B
4.1×
price / book
Earnings yield
up 3.8%
EBIT / enterprise value
Cheaper than
49%
of the market · around average
Revenue growth
up 6%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
up 13%
return on equity
Free cash margin
up 17%
$7.4B FCF
D/E
0.19
long-term debt / equity
Net debt / EBITDA
0.2×
Interest cover
—EBIT / interest
Piotroski tests
- profitability slipped from last year
- short-term liquidity weakened
- issued more shares
- assets working less efficiently
- profitable on its assets
- generating cash from operations
- profits backed by cash
- reduced long-term debt
- gross margin widened
Repair signals
- Long-term debt down 22% ($12.6B → $9.9B)
- Gross margin 55.4% → 56.4%
Trade setup
ATR%
2.6%
$2.72 a day · 2×ATR $100.77
RS
44 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
0.94
50 sessions
Implied move
—
no scheduled report
Contractions
3
14% → 9% → 8%
Pivot
$106.35
0.1% below
Volume dry-up
1.1×
10 vs 50 sessions
Trend template · 4 of 8
- Price above the 150 and 200-day averages: passes
- 150-day average above the 200-day: fails
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: passes
- At least 30% above the 52-week low: fails
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Oct 21, 2026
Results reaction
Oct 21, 2026+1% vs market2 sessions after results
Options
$1.9M27.4% IV · activity
Financials
- Gross 56%
- Net 15%
- Free cash 17%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $34.6B | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B |
| Gross margin | 57% | 57% | 56% | 55% | 55% | 56% |
| Operating income | $5.4B | $8.4B | $8.4B | $6.5B | $6.8B | $8.1B |
| Net income | $4.5B | $7.1B | $6.9B | $5.7B | $13.4B | $6.5B |
| Net margin | 13% | 16% | 16% | 14% | 32% | 15% |
| Earnings per share | $2.52 | $3.95 | $3.93 | $3.27 | $7.67 | $3.73 |
| Free cash flow | $5.7B | $8.6B | $7.8B | $5.1B | $6.4B | $7.4B |
| Free cash margin | 17% | 20% | 18% | 13% | 15% | 17% |
| Cash | $6.8B | $9.8B | $9.9B | $6.9B | $7.6B | $8.5B |
| Long-term debt | $18.5B | $17.3B | $14.5B | $13.6B | $12.6B | $9.9B |
| Shareholders' equity | $32.8B | $35.8B | $36.7B | $38.6B | $47.7B | $52.1B |
| Shares outstanding | 1.98bn | 1.99bn | 1.99bn | 1.99bn | 1.99bn | 2bn |
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $99 – $113 ±6.7% by Nov 27, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 27.4% priced · 23.4% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: no change
Positioning
- Premium traded
- $1.9M calls $1.6M · puts $285,194 · latest session
- 0.18× -0.41 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls -12.97k · puts -16.06k past week
For options traders: ATM IV 27.4% (+0.2% 1w) · 1m ÷ 3m IV 1.05 · 25Δ skew 2.5 pts · Net GEX $24.3M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Apr 29, 2026 | Quarterly ↗ | Mar 31, 2026 | 29d |
| Feb 20, 2026 | Annual ↗ | Dec 31, 2025 | 51d |
| Oct 29, 2025 | Quarterly ↗ | Sep 30, 2025 | 29d |
| Jul 30, 2025 | Quarterly ↗ | Jun 30, 2025 | 30d |
| Apr 30, 2025 | Quarterly ↗ | Mar 31, 2025 | 30d |
| Feb 21, 2025 | Annual ↗ | Dec 31, 2024 | 52d |
| Oct 31, 2024 | Quarterly ↗ | Sep 30, 2024 | 31d |
| Jul 31, 2024 | Quarterly ↗ | Jun 30, 2024 | 31d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 16, 2024 | Annual ↗ | Dec 31, 2023 | 47d |
| Nov 1, 2023 | Quarterly ↗ | Sep 30, 2023 | 32d |
| Aug 3, 2023 | Quarterly ↗ | Jun 30, 2023 | 34d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 21, 2026 | Results ↗ |
| Oct 21, 2026 | Other events ↗ |
| Aug 20, 2026 | Regulation FD · Other events ↗ |
| Jul 16, 2026 | Results ↗ |
| Apr 27, 2026 | Director or officer change · Charter or bylaws · Shareholder vote ↗ |
| Apr 17, 2026 | Other events ↗ |
| Apr 16, 2026 | Results ↗ |
| Mar 23, 2026 | Other events ↗ |
| Mar 9, 2026 | Material agreement · New obligation ↗ |
| Feb 26, 2026 | Material agreement ↗ |
| Feb 20, 2026 | Charter or bylaws ↗ |
| Jan 22, 2026 | Results ↗ |